Publications by authors named "David Yocum"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

2,402,138

Total Likes

46,666

Extended Reach

2,453,202

Social Features

27
A
A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis.
Kasia Owczarczyk, Preeti Lal, Alexander R Abbas, Kristen Wolslegel, Cecile T J Holweg, David Yocum

Sci Transl Med· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone marrow edema is the most specific finding for rheumatoid arthritis (RA) on noncontrast magnetic resonance imaging of the hands and wrists: a comparison of patients with RA and healthy controls.
Ewa Olech, John V Crues, David E Yocum, Joan T Merrill

J Rheumatol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of a sixteen-week training program on strength, pain, and function in rheumatoid arthritis patients.
Hilary G Flint-Wagner, Jeffrey Lisse, Timothy G Lohman, Scott B Going, Terri Guido, David E Yocum

J Clin Rheumatol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using extremity magnetic resonance imaging to assess and monitor early rheumatoid arthritis: the optimal joint combination to be scanned in clinical practice.
Ewa Olech, Jane E Freeston, Philip G Conaghan, Elizabeth M A Hensor, Paul Emery, David Yocum

J Rheumatol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A modification of the Omeract RA MRI score for erosions for use with an extremity MRI system with reduced field of view.
Jane E Freeston, Ewa Olech, David Yocum, Elizabeth M A Hensor, Paul Emery

Ann Rheum Dis· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis.
Mahboob U Rahman, Ingrid Strusberg, Piet Geusens, Alberto Berman, David Yocum

Ann Rheum Dis· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, randomized, open study to evaluate the impact of an electronic data capture system on the care of patients with rheumatoid arthritis.
Joseph Huffstutter, W David Craig, Gregory Schimizzi, John Harshbarger, Jeffrey Lisse, David Yocum

Curr Med Res Opin· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.
Daniel E Furst, Norman Gaylis, Vance Bray, Ewa Olech, David Yocum

Ann Rheum Dis· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0.
Thasia Woodworth, Daniel E Furst, Rieke Alten, Clifton O Bingham, David Yocum

J Rheumatol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response: office-based low-field extremity magnetic resonance imaging: is the glass half empty or half full?
David E Yocum, Philip G Conaghan, Ewa Olech, Charles G Peterfy

Arthritis Rheum· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial.
Rene Westhovens, David Yocum, John Han, Alberto Berman, Ingrid Strusberg

Arthritis Rheum· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does safety make a difference in selecting the right TNF antagonist?
Roy Fleischmann, David Yocum

Arthritis Res Ther· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective use of TNF antagonists.
David Yocum

Arthritis Res Ther· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severity of joint pain and Kellgren-Lawrence grade at baseline are better predictors of joint space narrowing than bone scintigraphy in obese women with knee osteoarthritis.
Steven A Mazzuca, Kenneth D Brandt, Donald S Schauwecker, Barry P Katz, Joan M Meyer, David E Yocum

J Rheumatol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial.
Kenneth D Brandt, Steven A Mazzuca, Barry P Katz, Kathleen A Lane, Kenneth A Buckwalter, David E Yocum

Arthritis Rheum· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
Marc C Hochberg, Mark G Lebwohl, Scott E Plevy, Kathryn F Hobbs, David E Yocum

Semin Arthritis Rheum· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoarthritis drug.
Steven A Mazzuca, Kenneth D Brandt, Barry P Katz, Kathleen A Lane, John D Bradley, David E Yocum

Arthritis Rheum· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
Michelle A Petri, Philip J Mease, Joan T Merrill, Robert G Lahita, Mark J Iannini, David E Yocum

Arthritis Rheum· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased activation-induced cell death in peripheral lymphocytes of rheumatoid arthritis patients: the mechanism of action.
Xiaolei Tang, David E Yocum, David Dejonghe, Kathryn Nordensson, Douglas F Lake

Immunology· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.
Laurie Bergstrom, David E Yocum, Neil M Ampel, Isidro Villanueva, Jeffrey Lisse

Arthritis Rheum· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune activation and depression in women with rheumatoid arthritis.
Alex J Zautra, David C Yocum, Isidro Villanueva, Bruce Smith, Mary C Davis

J Rheumatol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial.
David E Yocum, Daniel E Furst, Jeffrey L Kaine, Andrew R Baldassare, Jon T Stevenson

Arthritis Rheum· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterizing a soluble survival signal for activated lymphocytes from CD14+ cells.
Xiaolei Tang, David E Yocum, David DeJonghe, Kathy Nordensson

Immunology· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
Daniel E Furst, Kenneth Saag, M Roy Fleischmann, Yvonne Sherrer, Joel A Block, David Yocum

Arthritis Rheum· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis